– Dr. Lilienthal brings over 20 years of global biopharmaceutical experience, leading the development and commercialization of innovative medicines across multiple therapeutic areas including psychiatry and neurology – NEW YORK, April 5, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain…


Previous articlePT307 – Kathryn L. Tucker, JD – The Right to Try Act and the Battle for Psilocybin Access
Next articlePsychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by 1m Shares; 6 Projects Readers are Working On